This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

K&L Consulting Services Expands Partnership With Medidata Solutions

Stocks in this article: MDSO

Strengthening its clinical research service offerings in China and the US, contract research organization (CRO) K&L Consulting Services (K&L), Inc. has expanded its relationship with Medidata Solutions (NASDAQ: MDSO) by achieving multiple accreditations in the Medidata Clinical Cloud. With this milestone, K&L is now accredited to provide services around the industry-leading Medidata Rave ® system for electronic data capture (EDC) and clinical data management (CDM) as well as randomization services utilizing Medidata Balance TM.

With a focus on biostatistical analysis, data standardization and a prominent presence in China, K&L joined the Medidata Partner Program in 2011 as a Medidata Services Partner to help serve sponsors within Asia and abroad. Impressed with Medidata’s standards-based approach to end-to-end clinical development, K&L saw value in extending the partnership to take greater advantage of Rave's easy-to-use platform and streamlined processes to help sponsors prepare regulatory submissions. K&L is currently utilizing Medidata Rave for several studies within Asia; and with its continued growth in the region, it expects the Medidata platform to play a vital role in helping sponsors streamline their clinical trials.

  • “Partnering with Medidata enables us to offer sponsors state-of-the-art solutions for the critically important activities of randomization, electronic data capture and clinical data management,” said Xin Ke, PhD, president, K&L. “The Medidata Clinical Cloud, combined with our sophisticated services, provides sponsors with a highly-valued offering that ultimately reduces risk and leads to faster drug approvals.”

The Medidata accreditations position K&L to serve as a single source for Balance-related randomization design services and Rave-related services, including end user training, study build, reporting, outputs, integrations and migrations. Using Balance and Rave, sites can use just one browser interface—Medidata Rave—to randomize subjects and manage clinical data entry and reporting.

  • “With these accreditations, K&L strengthens its commitment to providing sponsors with increasing efficiencies across their clinical trials,” said Steve Heath, vice president of channel sales at Medidata Solutions. “We’re excited to collaborate with K&L to help life science organizations both in the US and the growing market in China.”

Medidata first announced its channel partner program in April 2005 to enable select CROs and other service providers to offer implementation services for the Medidata Rave system for EDC and CDM. Since then, the Medidata Partner Program has grown to include more than 30 partners in the US, Europe and Asia, ranging from smaller clinical consultancies to large, global CROs. The program offers eight accreditations across the Medidata platform and supports partners with a variety of on-demand resources to help them optimize sponsors’ clinical trials.

Connect with Medidata:

About K&L Consulting Services, Inc.

K&L Consulting Services, Inc. is a contract research organization (CRO) offering data management, biostatistics, statistical programming, and medical writing as well as CDISC compliant eSubmission services to the pharmaceutical, biotechnology and medical device industries worldwide. Their services encompass end-to-end solutions utilizing industry data standards and rigorous operating procedures that enhance a sponsor's ability to get their products approved faster at minimum risk and lower cost in order to meet patients’ needs for advanced medicines.

About Medidata Solutions Worldwide

Medidata Solutions is a leading global provider of cloud-based clinical development solutions that enhance the efficiency of customers’ clinical trials. Medidata’s advanced platform lowers the total cost of clinical development by optimizing clinical trials from concept to conclusion: from study and protocol design, trial planning and budgeting, site negotiation, clinical portal, trial management, randomization and trial supply management, clinical data capture and management, safety events capture, medical coding to business analytics. Our diverse life science customer base spans biopharmaceutical companies, medical device and diagnostic companies, academic and government institutions, CROs and other research organizations, and includes more than 20 of the top 25 global pharmaceutical companies as well as organizations of all sizes developing life-enhancing medical treatments and diagnostics.

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,777.92 -0.23 -0.00%
S&P 500 2,063.95 +2.72 0.13%
NASDAQ 4,755.6560 +7.26 0.15%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs